

CERTARA[®]

CODEX Clinical Outcomes Databases

Psoriasis (PSO)



Curated clinical trial data for earlier, confident decisions

Certara's Clinical Trial Outcomes Database (CODEX) is an expertly curated database of clinical trial data for marketed and pipeline drugs, covering 8 therapeutic areas and 70+ indications. It includes structured and unstructured data that can be downloaded and integrated with internal datasets to support modeling and simulation, enabling earlier, more confident drug development decisions.

With CODEX, you can:



Identify the right trial populations

analyze clinical data to identify target populations for new studies.



Improve study design

refine sample size calculations to reduce costs and increase success rates.



Strengthen regulatory strategy

review integrated summaries of safety and efficacy (ISS/ISE) for similar products to inform regulatory approval strategies.



Demonstrate commercial viability

run economic models to generate additional data points that can be used to demonstrate value to payers and in competitive pricing assessments.

Model-based meta-analysis (MBMA)

MBMA leverages CODEX databases and pharmacology models to increase development productivity, quantitatively inform portfolio decisions, and improve clinical trial success. It optimizes trial design, including timing, endpoints, and dosing, as well as competitive landscape assessment. MBMA also bridges across studies, allowing comparison of treatments and patient populations that may not have been evaluated within the same trial.



~383 studies

Key Efficacy & Biomarker
Endpoints (PASI75, PASI
score, PASI90, DLQI)



~137,901 patients

All systemic or novel
pharmacological treatments with
primary focus on biologics and
synthetic DMARDs



~205,326

Longitudinal Data Points – Format
available in Excel and CODEX
(Clinical Outcomes Database
Explorer)

A comprehensive repository of PSO clinical outcomes

The CODEX Psoriasis (PSO) Database provides utility across the drug development continuum to inform critical decisions that determine not only a drug's successful performance during a trial, but also a drug's profile within a competitive landscape. The PSO Database highlighted here is curated to document clinical efficacy and biomarker information from all randomized placebo and active controlled trials in Psoriasis & Psoriatic Arthritis patients. Trials found in this database also include washout designs and add on designs.

Treatment	Class	Studies
secukinumab	anti-IL-17A	48
adalimumab	anti-TNF	42
ustekinumab	anti-IL-12/23	40
etanercept	anti-TNF	33
apremilast	PDE4 inhibitor	21
guselkumab	anti-IL-23	18
ixekizumab	anti-IL-17A	18
risankizumab	anti-IL-23	16
brodalumab	anti-IL-17RA	14

Table 1. The top 9 drugs in the CODEX PSO database




Figure 1. Snapshot of select treatments; PASI75 time course




Figure 2. PASI90 time course for trials with adalimumab

Discover how CODEX can empower more confident decisions.

To learn more or request a demo, visit certara.com/codex

About Certara

Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,600 biopharmaceutical companies, academic institutions and regulatory agencies across 70 countries. Visit certara.com | Copyright ©2026 Certara. All rights reserved.